Government watchdog finds that most but not all generic drug prices are falling

Government watchdog finds that most but not all generic drug prices are falling

A new government investigation found that most but not all prices for generic drugs dispensed by Medicare Part D fell from 2010 to 2015.

Report: 3 tips for pharma to provide beyond-the-pill services

Report: 3 tips for pharma to provide beyond-the-pill services

Physicians are seeking beyond-the-pill services from drugmakers, but few sales reps shares details with docs about these programs, a new report finds.

Five things for pharma marketers to know: Wednesday, July 27, 2016

Five things for pharma marketers to know: Wednesday, July 27, 2016

IBM to help analyze data about the spread of Zika; Grassley to investigate Part D program; Lilly CEO to retire

Five things for pharma marketers to know: Wednesday, July 20, 2016

Five things for pharma marketers to know: Wednesday, July 20, 2016

Spending on CME rose in 2015; the FDA approves Valeant's Relistor; the Justice Department aims to block insurer merger

No free lunch for docs: Sponsored meals linked to more prescriptions

No free lunch for docs: Sponsored meals linked to more prescriptions

A new analysis suggests that $20 industry-sponsored meals may sway docs' prescribing habits.

Panel: Why data is the first step in telling a human story

Panel: Why data is the first step in telling a human story

The ability to pair data with a story or a human emotion is often easier for women.

The CIO, reimagined for pharma

The CIO, reimagined for pharma

Despite the increasing importance of the CIO post, top technology professionals still find it hard to break into the uppermost ranks at life-sciences companies.

Pharma is reluctant to adopt digital in R&D: survey

Pharma is reluctant to adopt digital in R&D: survey

Only 55% of the surveyed pharmaceutical executives said they are adopting digital as a key strategy in R&D.

Five things for pharma marketers to know: Thursday, May 26, 2016

Five things for pharma marketers to know: Thursday, May 26, 2016

BIO report finds success rate in Phase-I is 10%; Dunsire departs Forum after failed trials; the FDA issues two warning letters

Conflicting polls highlight uncertainty about the public's opinion of pharma

Conflicting polls highlight uncertainty about the public's opinion of pharma

Two recent polls paint a complicated picture of the public's opinion of the pharma industry.

Five things for pharma marketers to know: Friday, May 20, 2016

Five things for pharma marketers to know: Friday, May 20, 2016

Keytruda's survival benefit is reinforced by new study; drugmakers reference patient-assistance programs in debate over drug prices; China cuts drug prices

Ponemon: Cybercrime is top cause for healthcare data breaches

Ponemon: Cybercrime is top cause for healthcare data breaches

A 69% majority of healthcare organizations said they believe their industry is more vulnerable to data breaches than other business sectors.

U.S. drug spend jumped 12% in 2015

U.S. drug spend jumped 12% in 2015

2015 marks the second straight double digit increase in spend, which was driven by recent launches and specialty brands.

Five things for pharma marketers to know: Friday, April 8, 2016

Five things for pharma marketers to know: Friday, April 8, 2016

Analyst survey says docs want outcomes benefit from PCSK9s; Allergan licenses early-stage Alzheimer's drugs; Pfizer and IBM partner in Parkinson's disease

Eli Lilly's failed trial could spell the end for CETP inhibitors

Eli Lilly's failed trial could spell the end for CETP inhibitors

The results of a failed trial for Lilly's CEPT inhibitor has analysts saying there is little hope for Merck's drug in the same class.

Healthcare industry seeks to reform its position as hacking target

Healthcare industry seeks to reform its position as hacking target

Given the value of its data and its relatively backward security measures, the healthcare industry has become a prime target for hackers. But industry experts say changes are afoot.

Easy navigation beats out trustworthiness for health info, survey finds

Easy navigation beats out trustworthiness for health info, survey finds

Consumers are more likely to use health information websites they find easier to navigate than those perceived as trustworthy, like government sites, new research shows.

Five things for pharma marketers to know: Tuesday, March 1, 2016

Five things for pharma marketers to know: Tuesday, March 1, 2016

Analysis questions Addyi's effectiveness; Horizon is subpoenaed about its patient assistance programs; AstraZeneca sells non-U.S. rights to constipation drug

Five things for pharma marketers to know: Thursday, December 3, 2015

Five things for pharma marketers to know: Thursday, December 3, 2015

Healthcare spending rose in 2014; Publicis reorganizes its agency network; proposed New Jersey bill would punish drugmakers that move abroad

Data Management: Not If, But When

Data Management: Not If, But When

Healthcare may seem to have been unscarred by the ongoing rash of high-profile cyber-attacks, at least compared with retail and financial organizations. But to hear security pros tell it, the industry is increasingly finding itself as much of a target as companies in other sectors—if not more of one. Karen Epper Hoffman surveys the potential damage

IMS Health: Drug spend will steadily rise through 2020

IMS Health: Drug spend will steadily rise through 2020

Specialty medicines will keep drug spend trending upward through the next five years.

Is pharma's access to physicians decreasing or increasing?

Is pharma's access to physicians decreasing or increasing?

A pair of surveys paint a complicated picture of what direction pharma access to healthcare providers is going.

Drugmakers spend too much on marketing: Kaiser poll

Drugmakers spend too much on marketing: Kaiser poll

The public said drugmakers spend too much money on marketing to doctors and patients

Pharma's acceptance of transparency programs matures as reporting becomes global

Pharma's acceptance of transparency programs matures as reporting becomes global

Initiatives in Europe follow the US example when it comes to requiring manufacturers to report information about financial relationships with physicians.

Analysis shows pharma is getting better at R&D

Analysis shows pharma is getting better at R&D

An analysis of R&D data from 14 large drugmakers found that pharma is having renewed success in bringing medicines to market.

Five things for pharma marketers to know: Tuesday, September 22, 2015

Five things for pharma marketers to know: Tuesday, September 22, 2015

Report finds Americans overpay for cancer drugs; Clinton proposes end to pharma DTC as a tax write-off; Gilead HCV combo is effective across all strains of the virus

Smart devices will improve pharma sales: survey

Smart devices will improve pharma sales: survey

Accenture found that life-sciences executives believe that smart tools and devices will be the catalyst for drugmakers to move forward with beyond-the-pill initiatives.

Today the clinical trial, tomorrow the world

Today the clinical trial, tomorrow the world

As the value proposition of real-world data to drugmakers becomes increasingly attractive, services companies are partnering to capitalize on the opportunity.

Five things for pharma marketers to know: Thursday, September 10, 2015

Five things for pharma marketers to know: Thursday, September 10, 2015

Cardiologists say that up to 15% of their patients could be on PCSK9 inhibitors next year; FDA committee to evaluate new Oxycodone version

Pharma sales forces should act more like 'outcomes advocates'

Pharma sales forces should act more like 'outcomes advocates'

Sales reps that focus on creating value for HCPs could find new opportunities and improved access to those physicians, according to Accenture.

Poll: Majority of Americans support government negotiation of drug prices

Poll: Majority of Americans support government negotiation of drug prices

A new poll conducted by the Kaiser Family Foundation found that most Americans believe drugmakers should be required to release information to the public about how they set drug prices.

Most docs are in the dark about biosimilars: survey

Most docs are in the dark about biosimilars: survey

Less than half of 300 doctors polled in a QuantiaMD survey could name a biosimilar that's under consideration for approval, and only 17% said they're very likely to prescribe one.

Some heartburn drugs linked to increased risk of heart attack

A data-mining analysis of patient records found a significant increase in the chance of heart attack for those taking proton-pump inhibitors.

New guidelines recommend wait-and-see strategy for sinus infections

The American Academy of Otolaryngology said taking antibiotics for sinus infections is a slightly better treatment strategy than waiting it out.

Survey suggests doctors increasingly look for digital engagement

A new survey from Cegedim Relationship Management claims that digital tools are being underutilized and represent an opportunity to meet the demands of HCPs.

Better Rx coverage associated with outcomes lift: study

Better Rx coverage associated with outcomes lift: study

A study funded and conducted in part by the CVS Research Institute found that an expansion of prescription-drug benefits could mean better health outcomes as well as reduced spending.

Millennials don't care about traditional healthcare: study

Millennials don't care about traditional healthcare: study

Members of the 13-32 age group were less likely to agree that preventive care is the most important factor in staying healthy, compared to Baby Boomers and Gen-Xers.

Point-of-care messaging growth surpasses DTC growth: study

Point-of-care messaging growth surpasses DTC growth: study

As patients spend more time in waiting rooms where they are primed to learn about their health, POC promotions are becoming a more essential part of the marketing mix, researchers find.

Sharecare scales up again with QualityHealth buy

Sharecare scales up again with QualityHealth buy

Complementary solutions to drive growth with health plans as well as pharma clients, companies say.

Health systems are embracing value-based care: survey

Health systems are embracing value-based care: survey

Despite hurdles of practitioner buy-in and legacy IT, value-based care is on pace to overtake fee-for-service.

Rate of Sovaldi non-adherence points to need for patient support

Rate of Sovaldi non-adherence points to need for patient support

A mélange of new treatments awaiting approval and a lack of patient support are driving down drug utilization for Gilead's HCV blockbuster, according to a new study.

OPINION

Email Newsletters